13F Holdings
中文EN

HIND Vyome Holdings, Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1427570 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-55.6%
TTM net income YoY59.8%
TTM EPS YoY100.2%
Revenue 3-yr CAGR-75.0%
Net income 3-yr CAGR—

Margins

Gross margin50.4%
Operating margin-2,853.6%
Net margin-2,455.6%
FCF margin—
EBITDA margin-2,846.7%

Returns

ROE-95.7%
ROA-48.0%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets24.0%
Debt / equity0.00x
Current ratio3.68x
Interest coverage-229.34x

Cash quality & payout

Operating cash flow / net income1.18x
Accruals ratio8.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$319,714$256,944$8.68M$11.24M$13.60M
Cost of revenue$100,943$61,974$3.13M$4.44M$5.25M
Gross profit$218,771$194,970$5.55M$6.80M$8.35M
R&D expense$588,258$285,391$2.31M$2.54M$2.37M
SG&A expense$2.37M$898,572$10.32M$14.09M$8.89M
Operating income-$10.45M-$1.01M-$15.38M-$46.35M-$57.88M
Interest expense$146,641$206,004———
Pretax income—-$7.09M-$11.34M-$46.59M-$63.42M
Income tax—$39,000$52,000-$380,000-$274,000
Net income-$10.26M-$1.45M-$11.39M-$46.21M-$63.15M
EBITDA-$10.44M-$988,993-$15.26M-$46.02M-$57.65M
EPS (basic)-4.86-6,001.39-110.87-108.90-288.97
EPS (diluted)-4.86-6,001.39-110.87-108.90-288.97
Weighted avg. shares (diluted)2.16M241102,707424,390218,522
Balance sheet
Cash & equivalents$4.98M$101,904$16,647$3.96M$22.82M
Receivables$325$2,294$1.70M——
Inventory—$2.46M$3.74M$3.61M$3.00M
Current assets$5.44M$302,046$10.30M$9.91M$29.94M
PP&E, net$46,393$59,179$60,000$698,000$1.45M
Intangibles$314,191$314,191—$260,000$13.88M
Total assets$6.50M$1.38M$10.66M$11.14M$52.53M
Current liabilities$2.74M$5.74M$3.78M$7.48M$7.53M
Short-term debt—$811,000———
Total liabilities$2.74M$5.77M$4.00M$7.48M$8.20M
Shareholders' equity$2.44M-$4.39M$6.66M$3.66M$44.33M
Shares outstanding5.92M0404,437519,219356,641
Cash flow statement
Operating cash flow-$3.75M-$614,136-$16.96M-$21.90M-$15.38M
Capital expenditure——$43,000$131,000$352,000
Free cash flow——-$17.00M-$22.03M-$15.73M
Investing cash flow—$315-$10,000-$92,000$1.85M
Financing cash flow$8.65M$697,951$17.57M$3.13M$33.30M
Depreciation & amortization$11,985$17,347$121,000$330,000$232,000
Stock-based compensation$577,128$184,000$766,000$2.09M$12.23M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.